Regenxbio公司RGX-202疗法显示微肌营养不良蛋白表达与功能改善显著相关

美股速递05-14

Regenxbio公司公布的最新数据显示，其基因疗法候选产品RGX-202在临床试验中展现出令人鼓舞的结果。研究证实，患者体内微肌营养不良蛋白的表达水平与其运动功能的临床改善之间存在显著的正相关性。

这一发现为RGX-202治疗杜氏肌营养不良症的有效性提供了关键的科学依据，表明提升目标蛋白的表达可直接转化为患者获益。公司将继续推进该疗法的临床开发，以评估其长期安全性与疗效。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1187547111?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-14 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187547111","market":"us","top_or_hot":-1,"title":"Regenxbio公司RGX-202疗法显示微肌营养不良蛋白表达与功能改善显著相关","media":"美股速递","content":"<p>Regenxbio公司公布的最新数据显示，其基因疗法候选产品RGX-202在临床试验中展现出令人鼓舞的结果。研究证实，患者体内微肌营养不良蛋白的表达水平与其运动功能的临床改善之间存在显著的正相关性。</p>\n<p>这一发现为RGX-202治疗杜氏肌营养不良症的有效性提供了关键的科学依据，表明提升目标蛋白的表达可直接转化为患者获益。公司将继续推进该疗法的临床开发，以评估其长期安全性与疗效。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regenxbio公司RGX-202疗法显示微肌营养不良蛋白表达与功能改善显著相关</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegenxbio公司RGX-202疗法显示微肌营养不良蛋白表达与功能改善显著相关\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-14 19:01 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regenxbio公司公布的最新数据显示，其基因疗法候选产品RGX-202在临床试验中展现出令人鼓舞的结果。研究证实，患者体内微肌营养不良蛋白的表达水平与其运动功能的临床改善之间存在显著的正相关性。\n这一发现为RGX-202治疗杜氏肌营养不良症的有效性提供了关键的科学依据，表明提升目标蛋白的表达可直接转化为患者获益。公司将继续推进该疗法的临床开发，以评估其长期安全性与疗效。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RGNX","symbol_name":"Regenxbio Inc","start_time":0,"source_url":"","article_id":"1187547111","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187547111","pubTimestamp":1778756494,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Regenxbio公司公布的最新数据显示，其基因疗法候选产品RGX-202在临床试验中展现出令人鼓舞的结果。研究证实，患者体内微肌营养不良蛋白的表达水平与其运动功能的临床改善之间存在显著的正相关性。\n这一发现为RGX-202治疗杜氏肌营养不良症的有效性提供了关键的科学依据，表明提升目标蛋白的表达可直接转化为患者获益。公司将继续推进该疗法的临床开发，以评估其长期安全性与疗效。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"RGNX":"Regenxbio Inc","BK4505":"高瓴资本持仓","BK4563":"昨日强势股","BK4139":"生物科技"},"translate_title":"Regenxbio RGX-202 Therapy Shows Significant Correlation between Microdystrophin Expression and Functional Improvement","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGNX":1},"content_text":"Regenxbio公司公布的最新数据显示，其基因疗法候选产品RGX-202在临床试验中展现出令人鼓舞的结果。研究证实，患者体内微肌营养不良蛋白的表达水平与其运动功能的临床改善之间存在显著的正相关性。\n这一发现为RGX-202治疗杜氏肌营养不良症的有效性提供了关键的科学依据，表明提升目标蛋白的表达可直接转化为患者获益。公司将继续推进该疗法的临床开发，以评估其长期安全性与疗效。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187547111","isCrawlerRequest":true}